期刊文献+

血清MMP-9和ICAM-1水平对非小细胞肺癌骨转移诊断和预后的意义 被引量:5

Diagnostic and prognostic significance of serum MMP-9,ICAM-1 in non-small cell lung cancer patients with bone metastasis
下载PDF
导出
摘要 目的探讨基质金属蛋白酶-9(MMP-9)和细胞间粘附分子-1(ICAM-1)在非小细胞肺癌(NSCLC)伴骨转移患者血清中的表达及其对预后的意义。方法用ELISA方法检测10例健康对照者和70例初治NSCLC患者空腹血MMP-9和ICAM-1的表达,其中40例NSCLC患者伴骨转移Ⅳ期,30例Ⅰ-Ⅱ期。结果伴骨转移Ⅳ期NSCLC患者血清MMP-9、ICAM-1水平高于Ⅰ-Ⅱ期NSCLC患者,且两者均高于健康对照者。血清MMP-9、ICAM-1水平与Ⅳ期伴骨转移患者的中位生存期显著相关,且血清MMP-9水平可作为Ⅳ期伴骨转移NSCLC的独立预后因素。结论 MMP-9和ICAM-1均伴随NSCLC的发生发展以及疾病的进展而升高,对MMP-9和ICAM-1表达的分析有助于评估Ⅳ期伴骨转移NSCLC患者的预后,同时积极针对患者转移灶的治疗可以明显延长Ⅳ期伴骨转移NSCLC患者生存期。 Objective To investigate the diagnostic and prognostic value of matrix metalloproteinases-9(MMP-9) and intercellular adhesion molecule-1(ICAM-1) in serum for stage Ⅳ non-small cell lung cancer(NSCLC) patients with bone metastasis.Methods ELISA method was used to measure MMP-9 and ICAM-1 concentrations of 40 stage Ⅳ and 30 stage Ⅰ/Ⅱ NSCLC patients of initial treatment and 10 controls.Results Serum levels of MMP-9 and ICAM-1 in patients of stage Ⅳ NSCLC were higher than that of stage Ⅰ/Ⅱ,also of the control.The concentrations of MMP-9 and ICAM-1 were significantly correlated with survival time.Cox regression analysis found that MMP-9 could be an independent prognostic factor for the stage Ⅳ patients with bone metastasis.Conclusion MMP-9 and ICAM-1 are involved in the progression of NSCLC.The serum levels of MMP-9 and ICAM-1 might be a helpful role in estimating the prognosis of stage Ⅳ NSCLC patients with bone metastasis.Furthermore,the use of efficious therapeutic strategies can contribute to longer survival time.
出处 《临床肿瘤学杂志》 CAS 2010年第8期680-684,共5页 Chinese Clinical Oncology
基金 国家自然科学基金(30872991) 上海市浦江人才发展计划(08PJ14073)
关键词 MMP-9 ICAM-1 非小细胞肺癌 预后 MMP-9 ICAM-1 Non-small cell lung cancer(NSCLC) Prognosis
  • 相关文献

参考文献24

  • 1Sekine I, Nokihara H, Yamamoto N, et al. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy [ J ]. Lung Cancer, 2009, 65 ( 2 ) : 219 - 222.
  • 2Costa L, Badia X, Chow E, et al. Impact of skeletal complications on patients quality of life, mobility, and functional independence [ J ]. Support Care Cancer, 2008, 16 ( 8 ) :879 - 889.
  • 3Iizasa T, Fujisawa T, Suzuki M, et al. Elevated levels of circulating plasma matrix metalloproteinase-9 in non-small cell lung cancer patients[ J]. Clin Cancer Res, 1999, 5 ( 1 ) : 149 - 153.
  • 4Yang SF, Hsieh YS, Lin CL, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in non-small cell lung cancer patients [ J ]. Clin Chim Acta, 2005, 354(1 -2) :91 -99.
  • 5Deryugina El, Quigley JP. Matrix metalloproteinases and tumor metastasis[J]. Cancer Metastasis Rev, 2006, 25( 1 ) :9 -34.
  • 6Gouyer V, Conti M, Devos P, et al. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with non-small cell lung carcinoma who undergo resection with curative intent [ J ]. Cancer, 2005, 103 ( 8 ) : 1676 - 1684.
  • 7Laack E, Kohler A, Kugler C, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer [ J]. Ann Oncol, 2002, 13 (10) :1550 - 1557.
  • 8Tang CH, Tan TW, Fu WM, et al. Involvement of matrix metal- loproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis [ J ]. Carcinogenesis, 2008, 29 ( 1 ) : 35 -43.
  • 9Sprenger A, Schardt C, Rotsch M, et al. Soluble intercellular adhesion molecule-1 in patients with lung cancer and benign lung diseases[J]. J Cancer Res Clin Oncol, 1997, 123(11- 12): 632 - 638.
  • 10Nutt JE, Durkan GC, Mellon JK, et al. Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epider- mal growth factor and its detection in urine [ J ]. BJU Int, 2003, 91(1) :99 -104.

同被引文献81

引证文献5

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部